Zentalis Pharmaceuticals (NASDAQ:ZNTL) Trading Down 7.1%

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) fell 7.1% during mid-day trading on Wednesday . The company traded as low as $11.63 and last traded at $11.68. 445,154 shares were traded during mid-day trading, a decline of 44% from the average session volume of 791,847 shares. The stock had previously closed at $12.57.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wedbush lifted their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a "neutral" rating in a report on Wednesday, February 28th. HC Wainwright restated a "buy" rating and issued a $46.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $38.57.

Zentalis Pharmaceuticals Stock Down 6.4 %

The stock has a market cap of $835.20 million, a price-to-earnings ratio of -2.61 and a beta of 1.73. The stock's fifty day moving average is $14.16 and its 200-day moving average is $13.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.09. As a group, equities research analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the transaction, the chief financial officer now owns 451,449 shares of the company's stock, valued at $5,164,576.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.10% of the company's stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Eventide Asset Management LLC raised its position in Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company's stock worth $175,134,000 after acquiring an additional 3,745,936 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 6.2% in the third quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company's stock valued at $105,047,000 after purchasing an additional 307,490 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Zentalis Pharmaceuticals by 10.9% in the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company's stock valued at $32,733,000 after purchasing an additional 212,872 shares during the last quarter. Decheng Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at $31,809,000. Finally, Wellington Management Group LLP increased its holdings in shares of Zentalis Pharmaceuticals by 0.5% in the third quarter. Wellington Management Group LLP now owns 1,917,105 shares of the company's stock valued at $38,457,000 after purchasing an additional 8,661 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.